ClinicalTrials.gg
CompletedNCT01159171Updated Aug 15, 2014Results posted

A Study of Avastin (Bevacizumab) and Oxaliplatin Plus Xeloda (Capecitabine) in Patients With Advanced Colorectal Cancer.

A Phase 2 interventional study of bevacizumab [Avastin] and capecitabine [Xeloda] in Colorectal Cancer, sponsored by Hoffmann-La Roche. Completed at 6 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-08-15.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies testing oxaliplatin in Colorectal Neoplasms — 21 open to participants now, 25 under way, 6 of them phase 3. Oxaliplatin · Colorectal Neoplasms.

Enrollment
90th of 183
50 · median 50
Started
2006
with 17 others
Phase 2
110 of 206
12 open now
Registered
131st of 206
by date
Lead sponsor
11 of 206
Hoffmann-La Roche

Among the 206 studies testing oxaliplatin in Colorectal Neoplasms, this one is the 90th largest by enrollment of the 183 interventional ones that give a count, is one of 18 that started in 2006, is one of 110 in phase 2, and was the 131st registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

21 of the 206 studies testing oxaliplatin in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About oxaliplatin

Oxaliplatin: first FDA approval 2002 (ELOXATIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies testing oxaliplatin in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This study will assess the efficacy and safety of treatment with the combination Avastin (bevacizumab) 5mg/kg iv every 2 weeks, Xeloda (capecitabine) 1000 mg po b.i.d. on Days 1-14 of every 28-day cycle and oxaliplatin 40mg/m2 iv weekly in patients with inoperable locally advanced or metastatic colorectal cancer. The anticipated time on study treatment is until disease progression.

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients >=18 years of age
  • Locally advanced or colorectal cancer
  • No previous treatment with chemotherapy for metastatic disease
  • Measurable and/or evaluable lesions

Exclusion criteria

Exclusion Criteria:

  • Radiotherapy within 4 weeks before study
  • Untreated or primary brain tumors
  • Chronic, daily treatment with high-dose aspirin (>325mg/day)
  • Co-existing , or malignancies diagnosed within the last 5 years, with the exception of basal and squamous cell cancer, or cervical cancer in situ
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    1

    Drug: bevacizumab [Avastin] · Drug: capecitabine [Xeloda] · Drug: oxaliplatin

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Objective Response (OR)

    Percentage of participants with OR was defined as the percentage of participants who achieved complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). CR was defined as disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. PR was defined as greater than or equal to (≥)30 percent (%) decrease under baseline of the sum of the longest diameter (LD) diameters of all target lesions. No unequivocal progression of non-target disease. No new lesions. Complete and partial responses must have been confirmed no less than 4 weeks after the criteria for response were first met.

    Time frame: Baseline, every 3 months to progression of disease or end of study (up to 24 months)

  2. Percentage of Participants by Best Overall Response

    Best response recorded from the start of treatment until disease progression. Based on assessment of CR, PR, stable disease (SD), or progressive disease (PD), according to RECIST. CR: disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. PR: ≥30% decrease under baseline of the sum of the LD diameters of all target lesions. CR and PR persist on repeat imaging study at least 4 weeks after initial documentation. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Reference is the smallest sum LD. PD: at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum longest diameter recorded or the appearance of one or more new lesions.

    Time frame: Baseline, every 3 months to progression of disease or end of study (up to 24 months)

Secondary outcomes

  1. Duration of Response - Percentage of Participants With an Event by 24 Months

    Duration of overall response (CR or PR) was calculated only for participants of the ITT population whose best overall response was CR or PR based on RECIST criteria. Duration of overall response was defined as the time from the date of the first assessment of CR or PR status until the date of progression or death. Data for participants who were alive without any objectively documented disease progression at the end of the study were censored as of the date of last contact.

    Time frame: Baseline, every 3 months to progression of disease or end of study (up to 24 months)

  2. Duration of Response

    Duration of overall response (CR or PR) was calculated for participants of the ITT population whose best overall response was CR or PR based on RECIST criteria. Duration of overall response was defined as the time from the date of the first assessment of CR or PR status until the date of progression or death. Data for participants who were alive without any objectively documented disease progression at the end of the study were censored as of the date of last contact. Mean time to event was estimated using the Kaplan-Meier method.

    Time frame: Baseline, every 3 months to progression of disease or end of study (up to 24 months)

  3. Duration of Stable Disease - Percentage of Participants With an Event by 24 Months

    Duration of stable response (CR, PR, or stable disease \[SD\]) was calculated only for participants of the ITT population whose best overall response was CR, PR, or SD based on RECIST criteria. Duration of overall response was defined as the time from the date of the first assessment of CR, PR, or SD status until the date of progression or death. Data for participants who were alive without any objectively documented disease progression at the end of the study were censored as of the date of last contact.

    Time frame: Baseline, every 3 months to progression of disease or end of study (up to 24 months)

  4. Duration of Stable Disease

    Duration of stable response (CR, PR, or SD) was calculated only for participants of the ITT population whose best overall response was CR, PR, or SD based on RECIST criteria. Duration of overall response was defined as the time from the date of the first assessment of CR, PR, or SD status until the date of progression or death. Data for participants who were alive without any objectively documented disease progression at the end of the study were censored as of the date of last contact. Mean time to event was estimated using the Kaplan-Meier method.

    Time frame: Baseline, every 3 months to progression of disease or end of study (up to 24 months)

  5. Time to Treatment Failure (TTF) - Percentage of Participants With an Event by 24 Months

    TTF was defined as the time in months from Day 1 until discontinuation of treatment for any reasons. These reasons included: death due to any cause, treatment toxicity (adverse event), insufficient therapeutic response (progression of disease), failure to return (lost to follow-up), refusing treatment (participant non-compliance), being unwilling to cooperate and withdrawing consent (participant withdrew consent).

    Time frame: Baseline, every month to end of treatment (up to 24 months)

  6. Time to Treatment Failure

    TTF was defined as the time in months from Day 1 until discontinuation of treatment for any reasons. These reasons included: death due to any cause, treatment toxicity (adverse event), insufficient therapeutic response (progression of disease), failure to return (lost to follow-up), refusing treatment (participant non-compliance), being unwilling to cooperate and withdrawing consent (participant withdrew consent). Mean TTF was estimated using the Kaplan-Meier method.

    Time frame: Baseline, monthly to end of study (up to 24 months)

  7. Time to Progression (TTP) - Percentage of Participants With an Event by 24 Months

    TTP was defined as the time time in months from Day 1 until the date of first documented progressive disease, or death due to any cause. Data for participants who were alive without disease progression at the end of study, or who were non-responder participants (without tumor assessment after baseline) were censored at Day 1.

    Time frame: Baseline, monthly to end of study (up to 24 months)

  8. Time to Progression

    TTP was defined as the time in months from Day 1 until the date of first documented progressive disease, or death due to any cause. Data for participants who were alive without disease progression at the end of study, or who were non-responder participants (without tumor assessment after baseline) were censored at Day 1. Mean TTP was estimated using the Kaplan-Meier method.

    Time frame: Baseline, monthly to end of study (up to 24 months)

  9. Overall Survival (OS) - Percentage of Participants With an Event by 24 Months

    OS was defined as the time in months from Day 1 until the date of death due to any cause. Data for participants who were alive at the end of the study were censored at the date of the last available follow-up visit.

    Time frame: Baseline, monthly to end of study (up to 24 months)

  10. Overall Survival

    OS was defined as the time in months from Day 1 until the date of death due to any cause. Data for participants who were alive at the end of the study were censored at the date of the last available follow-up visit. Mean OS was estimated using the Kaplan-Meier method.

    Time frame: Baseline, monthly to end of study (up to 24 months)

07

Results

Posted Aug 15, 2014

Participant flow

Participant flow — Overall Study
MilestoneBevacizumab + Oxaliplatin + Capecitabine
Started50
Completed0
Not completed50
Withdrew: Adverse event11
Withdrew: Progression of disease28
Withdrew: Protocol violation1
Withdrew: Need for surgery5
Withdrew: Medical decision4
Withdrew: Death1

Outcome measures

PrimaryPercentage of Participants With Objective Response (OR)

Percentage of participants with OR was defined as the percentage of participants who achieved complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). CR was defined as disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. PR was defined as greater than or equal to (≥)30 percent (%) decrease under baseline of the sum of the longest diameter (LD) diameters of all target lesions. No unequivocal progression of non-target disease. No new lesions. Complete and partial responses must have been confirmed no less than 4 weeks after the criteria for response were first met.

Time frame:
Baseline, every 3 months to progression of disease or end of study (up to 24 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Response (OR)
percentage of participantsBevacizumab + Oxaliplatin + Capecitabine
Percentage of Participants With Objective Response (OR)42.86 (0.31 to NA)
Statistical analysis
  • Bevacizumab + Oxaliplatin + Capecitabine · One sample exact binomial test · p = 0.0047 (One-sided p-value)
SecondaryDuration of Response - Percentage of Participants With an Event by 24 Months

Duration of overall response (CR or PR) was calculated only for participants of the ITT population whose best overall response was CR or PR based on RECIST criteria. Duration of overall response was defined as the time from the date of the first assessment of CR or PR status until the date of progression or death. Data for participants who were alive without any objectively documented disease progression at the end of the study were censored as of the date of last contact.

Time frame:
Baseline, every 3 months to progression of disease or end of study (up to 24 months)
Reported as:
Number · percentage of participants
Duration of Response - Percentage of Participants With an Event by 24 Months
percentage of participantsBevacizumab + Oxaliplatin + Capecitabine
Duration of Response - Percentage of Participants With an Event by 24 Months57.14
SecondaryDuration of Response

Duration of overall response (CR or PR) was calculated for participants of the ITT population whose best overall response was CR or PR based on RECIST criteria. Duration of overall response was defined as the time from the date of the first assessment of CR or PR status until the date of progression or death. Data for participants who were alive without any objectively documented disease progression at the end of the study were censored as of the date of last contact. Mean time to event was estimated using the Kaplan-Meier method.

Time frame:
Baseline, every 3 months to progression of disease or end of study (up to 24 months)
Reported as:
Mean · months
Duration of Response
monthsBevacizumab + Oxaliplatin + Capecitabine
Duration of Response8.31 ± 1.97
SecondaryDuration of Stable Disease - Percentage of Participants With an Event by 24 Months

Duration of stable response (CR, PR, or stable disease \[SD\]) was calculated only for participants of the ITT population whose best overall response was CR, PR, or SD based on RECIST criteria. Duration of overall response was defined as the time from the date of the first assessment of CR, PR, or SD status until the date of progression or death. Data for participants who were alive without any objectively documented disease progression at the end of the study were censored as of the date of last contact.

Time frame:
Baseline, every 3 months to progression of disease or end of study (up to 24 months)
Reported as:
Number · percentage of participants
Duration of Stable Disease - Percentage of Participants With an Event by 24 Months
percentage of participantsBevacizumab + Oxaliplatin + Capecitabine
Duration of Stable Disease - Percentage of Participants With an Event by 24 Months52.50
PrimaryPercentage of Participants by Best Overall Response

Best response recorded from the start of treatment until disease progression. Based on assessment of CR, PR, stable disease (SD), or progressive disease (PD), according to RECIST. CR: disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. PR: ≥30% decrease under baseline of the sum of the LD diameters of all target lesions. CR and PR persist on repeat imaging study at least 4 weeks after initial documentation. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Reference is the smallest sum LD. PD: at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum longest diameter recorded or the appearance of one or more new lesions.

Time frame:
Baseline, every 3 months to progression of disease or end of study (up to 24 months)
Reported as:
Number · percentage of participants
Percentage of Participants by Best Overall Response
percentage of participantsBevacizumab + Oxaliplatin + Capecitabine
CR4.08
PR38.78
SD38.78
PD8.16
SecondaryDuration of Stable Disease

Duration of stable response (CR, PR, or SD) was calculated only for participants of the ITT population whose best overall response was CR, PR, or SD based on RECIST criteria. Duration of overall response was defined as the time from the date of the first assessment of CR, PR, or SD status until the date of progression or death. Data for participants who were alive without any objectively documented disease progression at the end of the study were censored as of the date of last contact. Mean time to event was estimated using the Kaplan-Meier method.

Time frame:
Baseline, every 3 months to progression of disease or end of study (up to 24 months)
Reported as:
Mean · months
Duration of Stable Disease
monthsBevacizumab + Oxaliplatin + Capecitabine
Duration of Stable Disease10.09 ± 1.30
SecondaryTime to Treatment Failure (TTF) - Percentage of Participants With an Event by 24 Months

TTF was defined as the time in months from Day 1 until discontinuation of treatment for any reasons. These reasons included: death due to any cause, treatment toxicity (adverse event), insufficient therapeutic response (progression of disease), failure to return (lost to follow-up), refusing treatment (participant non-compliance), being unwilling to cooperate and withdrawing consent (participant withdrew consent).

Time frame:
Baseline, every month to end of treatment (up to 24 months)
Reported as:
Number · percentage of participants
Time to Treatment Failure (TTF) - Percentage of Participants With an Event by 24 Months
percentage of participantsBevacizumab + Oxaliplatin + Capecitabine
Time to Treatment Failure (TTF) - Percentage of Participants With an Event by 24 Months81.63
SecondaryTime to Treatment Failure

TTF was defined as the time in months from Day 1 until discontinuation of treatment for any reasons. These reasons included: death due to any cause, treatment toxicity (adverse event), insufficient therapeutic response (progression of disease), failure to return (lost to follow-up), refusing treatment (participant non-compliance), being unwilling to cooperate and withdrawing consent (participant withdrew consent). Mean TTF was estimated using the Kaplan-Meier method.

Time frame:
Baseline, monthly to end of study (up to 24 months)
Reported as:
Mean · months
Time to Treatment Failure
monthsBevacizumab + Oxaliplatin + Capecitabine
Time to Treatment Failure7.44 ± 0.84
SecondaryTime to Progression (TTP) - Percentage of Participants With an Event by 24 Months

TTP was defined as the time time in months from Day 1 until the date of first documented progressive disease, or death due to any cause. Data for participants who were alive without disease progression at the end of study, or who were non-responder participants (without tumor assessment after baseline) were censored at Day 1.

Time frame:
Baseline, monthly to end of study (up to 24 months)
Reported as:
Number · percentage of participants
Time to Progression (TTP) - Percentage of Participants With an Event by 24 Months
percentage of participantsBevacizumab + Oxaliplatin + Capecitabine
Time to Progression (TTP) - Percentage of Participants With an Event by 24 Months91.84
SecondaryTime to Progression

TTP was defined as the time in months from Day 1 until the date of first documented progressive disease, or death due to any cause. Data for participants who were alive without disease progression at the end of study, or who were non-responder participants (without tumor assessment after baseline) were censored at Day 1. Mean TTP was estimated using the Kaplan-Meier method.

Time frame:
Baseline, monthly to end of study (up to 24 months)
Reported as:
Mean · months
Time to Progression
monthsBevacizumab + Oxaliplatin + Capecitabine
Time to Progression9.61 ± 0.90
SecondaryOverall Survival (OS) - Percentage of Participants With an Event by 24 Months

OS was defined as the time in months from Day 1 until the date of death due to any cause. Data for participants who were alive at the end of the study were censored at the date of the last available follow-up visit.

Time frame:
Baseline, monthly to end of study (up to 24 months)
Reported as:
Number · percentage of participants
Overall Survival (OS) - Percentage of Participants With an Event by 24 Months
percentage of participantsBevacizumab + Oxaliplatin + Capecitabine
Overall Survival (OS) - Percentage of Participants With an Event by 24 Months89.90
SecondaryOverall Survival

OS was defined as the time in months from Day 1 until the date of death due to any cause. Data for participants who were alive at the end of the study were censored at the date of the last available follow-up visit. Mean OS was estimated using the Kaplan-Meier method.

Time frame:
Baseline, monthly to end of study (up to 24 months)
Reported as:
Mean · months
Overall Survival
monthsBevacizumab + Oxaliplatin + Capecitabine
Overall Survival20.23 ± 1.68

Adverse events

Collected over Adverse events (AEs) were collected form the date of first study-drug intake until 28 days after the date of last study-drug intake.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bevacizumab + Oxaliplatin + Capecitabine—18/49 (36.7%)48/49 (98%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventBevacizumab + Oxaliplatin + Capecitabine
SubileusGastrointestinal disorders3/49
DiarrheaGastrointestinal disorders2/49
Vena cava thrombosisVascular disorders2/49
Angina pectorisCardiac disorders1/49
Gastrointestinal obstructionGastrointestinal disorders1/49
Intestinal obstructionGastrointestinal disorders1/49
PainGeneral disorders1/49
Femur fractureInjury, poisoning and procedural complications1/49
DehydrationMetabolism and nutrition disorders1/49
SyncopeNervous system disorders1/49
Most frequent other events
Showing 10 of 35
Most frequent other events
EventBevacizumab + Oxaliplatin + Capecitabine
DiarrheaGastrointestinal disorders22/49
ParaesthesiaNervous system disorders22/49
NauseaGastrointestinal disorders19/49
VomitingGastrointestinal disorders15/49
Abdominal painGastrointestinal disorders14/49
Neuropathy peripheralNervous system disorders13/49
PyrexiaGeneral disorders12/49
HypertensionVascular disorders12/49
ThrombocytopeniaBlood and lymphatic system disorders11/49
AstheniaGeneral disorders11/49

Baseline characteristics

Safety population: all participants who received at least one dose of one study medication.

Age, Continuous
Age, Continuous(years)Bevacizumab + Oxaliplatin + Capecitabine
Mean59.08 ± 9.62
Sex: Female, Male
Sex: Female, Male(Participants)Bevacizumab + Oxaliplatin + Capecitabine
Female25
Male24
08

Study locations

6 sites
  • Aviano, 33081, Italy
  • Fano, 61032, Italy
  • Palermo, 90146, Italy
  • Rimini, 47900, Italy
  • Roma, 00135, Italy
  • Torino, 10126, Italy
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2006, a primary completion of Jul 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 4 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2010
First posted
Jul 9, 2010
Start
Jan 2006
Primary completionActual
Jul 2010
CompletionActual
Jul 2010
Results first posted
Aug 15, 2014
Last update
Aug 15, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01159171
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jul 9, 2010
Start date
Jan 2006
Primary completion
Jul 2010
Completion
Jul 2010
Results posted
Aug 15, 2014
Last update
Aug 15, 2014

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxaliplatin

Start the discussion